This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marcelin, A.-G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marcelin, A.-G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2005, p. 1739-1744, Vol. 49, No. 5
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.5.1739-1744.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Clinically Relevant Genotype Interpretation of Resistance to Didanosine

Anne-Geneviève Marcelin,1* Philippe Flandre,2 Juliette Pavie,3 Nathalie Schmidely,4 Marc Wirden,1 Olivier Lada,1 Dan Chiche,4 Jean-Michel Molina,2 Vincent Calvez,1 the AI454-176 Jaguar Study Team,{dagger}

Department of Virology, Pitié-Salpêtrière Hospital, Paris, France,1 INSERM, Paul Brousse Hospital, Villejuif, France,2 Department of Infectious Diseases, Saint Louis Hospital, Paris, France,3 BMS France Laboratory, Rueil, France4

Received 28 September 2004/ Returned for modification 12 November 2004/ Accepted 3 January 2005

We analyzed the didanosine (ddI) arm of the randomized, placebo-controlled Jaguar trial in order to define a genotypic score for ddI associated with virologic response. In this arm, 111 patients experiencing virologic failure received ddI in addition to their current combination therapy for 4 weeks. The impact of mutations in the reverse transcriptase gene on the virologic response to ddI was studied in univariate analysis. Genotypic score was constructed using step-by-step analyses first including only mutations associated to poorer virologic response (scored as +1), while secondarily, mutations associated to a better response (scored as –1) were also eligible. Eight mutations were associated with a reduced response to ddI, M41L, D67N, T69D, L74V, V118I, L210W, T215Y/F, and K219Q/E, and two mutations were associated with a better response, K70R and M184V/I. The best prediction of the virologic response to ddI was obtained with a composite score comprising mutations added and subtracted (set II, M41L + T69D + L74V+ T215Y/F + K219Q/E – K70R – M184V/I; P = 4.5 x 10–9) and by comparing that to only mutations added (set I, M41L + T69D + L74V + L210W + T215Y/F + K219Q/E; P = 1.2 x 10–7). Patients had a human immunodeficiency virus RNA reduction of 1.24, 0.84, 0.61, 0.40, and 0.07 log10 copies/ml when they were ranked as having a genotypic score II of –2, –1, or 0 or 1 and 2 mutations or more, respectively. In conclusion, we developed and validated a genotypic score, taking into account mutations negatively and positively impacting the virologic response to ddI.

* Corresponding author. Mailing address: Department of Virology, Pitié-Salpêtrière Hospital, 83 Boulevard de l'Hôpital, 75013 Paris, France. Phone: 33142177401. Fax: 33142177411. E-mail: anne-genevieve.marcelin{at}psl.ap-hop-paris.fr.

{dagger} Contributing members of the AI454-176 Jaguar Study Team are listed in Acknowledgments.

Antimicrobial Agents and Chemotherapy, May 2005, p. 1739-1744, Vol. 49, No. 5
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.5.1739-1744.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Descamps, D., Lambert-Niclot, S., Marcelin, A.-G., Peytavin, G., Roquebert, B., Katlama, C., Yeni, P., Felices, M., Calvez, V., Brun-Vezinet, F. (2009). Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients. J Antimicrob Chemother 63: 585-592 [Abstract] [Full Text]  
  • Marcelin, A.-G., Flandre, P., Molina, J.-M., Katlama, C., Yeni, P., Raffi, F., Antoun, Z., Ait-Khaled, M., Calvez, V. (2008). Genotypic Resistance Analysis of the Virological Response to Fosamprenavir-Ritonavir in Protease Inhibitor-Experienced Patients in CONTEXT and TRIAD Clinical Trials. Antimicrob. Agents Chemother. 52: 4251-4257 [Abstract] [Full Text]  
  • Marcelin, A.-G., Masquelier, B., Descamps, D., Izopet, J., Charpentier, C., Alloui, C., Bouvier-Alias, M., Signori-Schmuck, A., Montes, B., Chaix, M.-L., Amiel, C., Santos, G. D., Ruffault, A., Barin, F., Peytavin, G., Lavignon, M., Flandre, P., Calvez, V. (2008). Tipranavir-Ritonavir Genotypic Resistance Score in Protease Inhibitor-Experienced Patients. Antimicrob. Agents Chemother. 52: 3237-3243 [Abstract] [Full Text]  
  • Hu, Z., Giguel, F., Hatano, H., Reid, P., Lu, J., Kuritzkes, D. R. (2006). Fitness Comparison of Thymidine Analog Resistance Pathways in Human Immunodeficiency Virus Type 1. J. Virol. 80: 7020-7027 [Abstract] [Full Text]  
  • Wirden, M., Roquebert, B., Derache, A., Simon, A., Duvivier, C., Ghosn, J., Dominguez, S., Boutonnet, V., Ait-Arkoub, Z., Katlama, C., Calvez, V., Marcelin, A.-G. (2006). Risk Factors for Selection of the L74I Reverse Transcriptase Mutation in Human Immunodeficiency Virus Type 1-Infected Patients.. Antimicrob. Agents Chemother. 50: 2553-2556 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»